GET DAILY SIGNALSSilo Pharma (SILO) Declines -10.3% Over 30 Days as Dilution Concerns Persist
Key Takeaways
- Silo Pharma (SILO) shares declined about 10.3% over the last 30 days, sliding from a close near $1.45 to roughly $1.30.
- The pullback is part of a much steeper downtrend, with the stock down approximately 69% over the trailing three months.
- Equity-linked transactions, including software and intellectual-property acquisitions and a private placement, have renewed concerns about share dilution.
- Silo remains a developmental-stage biopharmaceutical company with limited revenue, leaving the micro-cap stock exposed to outsized price swings.
- Positive pipeline developments, including a U.S. patent allowance for lead candidate SPC-15, have not been enough to reverse the selling pressure.
Silo Pharma (SILO) Company Overview and Market Position
Silo Pharma, Inc. (SILO) is a developmental-stage biopharmaceutical company developing novel therapeutics for underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its lead program, SPC-15, is an intranasal serotonin 5-HT4 receptor agonist being advanced toward a first-in-human trial for PTSD. The company also develops SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer's disease and multiple sclerosis. Beyond its therapeutic pipeline, Silo operates QwikAgents, an AI-agent platform focused on enterprise workflow automation, and maintains a cryptocurrency treasury strategy. The company, which completed a 1-for-15 reverse stock split in June 2026, is a micro-cap with a market capitalization of roughly $2 million and limited revenue, trading on the Nasdaq Capital Market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Silo Pharma (SILO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SILO fell about 10.3%, from a closing price near $1.45 to roughly $1.30. The move was not linear: the stock slid sharply in mid-October, dropping from a close of $1.49 on October 12 to $1.22 the following session, before stabilizing in a range of roughly $1.13 to $1.33 through early November. That 30-day decline extends a far larger pullback. Over the trailing quarter, the shares have fallen approximately 69%, from a close near $4.21 in early August to the current level, reflecting sustained selling pressure across the summer and fall.
What Drove SILO Stock Price in the Last 30 Days
The most significant event in the 30-day window was a sharp mid-October selloff tied to equity-funded transactions. On October 1, Silo disclosed an asset purchase agreement with Norsight Consulting to acquire software and related intellectual property in exchange for a warrant covering up to 300,000 shares. On October 13, the company announced a separate software and IP acquisition from Larry King in exchange for 150,000 locked-up shares; the stock fell roughly 18% that session on elevated volume. On November 5, Silo entered purchase agreements for a private placement of 136,005 shares at $1.50 per share together with pre-funded warrants covering up to 430,661 shares, closing November 6 with expected net proceeds of about $815,000 for working capital. Collectively, these transactions increased the potential share count for a company with a very small float and reinforced concerns about dilution, outweighing positive news such as the U.S. patent allowance for SPC-15 announced in September. From what I see, these financing moves have clearly weighed on sentiment.
What Drove SILO Stock Performance Over the Last Quarter
The dominant theme over the last quarter has been a prolonged de-rating driven by repeated equity-linked capital raises and asset acquisitions. After trading above $4.00 in early August, the stock retreated through September and October as investors weighed the company's reliance on share-based consideration to fund technology purchases and its limited near-term revenue. The June 2026 reverse split and subsequent financing activity have further complicated the capital structure, and the shares have consistently traded well below their 52-week high. Positive milestones, including U.S., Canadian, and European patent activity around SPC-15 and the QwikAgents platform's expansion with NVIDIA model support, have provided intermittent support but have not reversed the broader downtrend.
SILO Stock Forecast Drivers: What Investors Should Watch Next
Investors are likely to focus on several factors in the months ahead: the planned Investigational New Drug submission and potential first-in-human trial for SPC-15, additional preclinical data for SP-26, and the commercial launch and early revenue contribution of the QwikAgents AI platform. Financing and capital structure remain key risks, given the company's pattern of equity-linked issuances and limited cash-generating operations, and further dilution could influence the share price. Macroeconomic conditions and broader sentiment toward pre-revenue biotech and micro-cap stocks may also affect volatility. These are considerations rather than forecasts, and the stock's low liquidity means price moves can be outsized in either direction. I’m watching this closely as the next catalysts approach.
Exploring Tickeron AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Trading Bots can help monitor volatile names such as SILO by highlighting automated strategies that align with different risk levels and timeframes. I’ve found these resources useful for gaining an additional perspective on momentum and potential entry points without replacing my own fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for SILO turns positive, indicating new upward trend
SILO saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 89 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SILO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +37.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where SILO advanced for three days, in 213 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SILO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SILO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SILO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. SILO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.466) is normal, around the industry mean (3.498). P/E Ratio (-0.348) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.910) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (28.736) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SILO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement